Enhanced Protective Efficacy Against Mycobacterium Tuberculosis Afforded by BCG Prime‐dna Boost Regimen in an Early Challenge Mouse Model is Associated with Increased Splenic Interleukin‐2‐producing CD4 T‐cell Frequency Post‐vaccination

Han Kang,Qin Yuan,Hui Ma,Zhi-Dong Hu,De-Ping Han,Kang Wu,Douglas B Lowrie,Xiao-Yong Fan

DOI: https://doi.org/10.1111/imm.12348

2014-01-01

Immunology

Abstract:Summary The development of improved vaccines and vaccination strategies against M ycobacterium tuberculosis has been hindered by a limited understanding of the immune correlates of anti‐tuberculosis protective immunity. Simple measurement of interferon‐ γ frequency or production per se does not provide adequate prediction of immune protection. In this study, we examined the relationship between T‐cell immune responses and protective efficacy conferred by the heterologous vaccination strategy, bacillus Calmette–Guérin ( BCG ) prime‐Ag85A DNA boost (B/D), in an early challenge mouse model of pulmonary tuberculosis. The results demonstrated that mice vaccinated with the B/D regimen had a significantly reduced bacillary load compared with BCG ‐vaccinated mice, and the reduction in colony‐forming units was associated with decreased pathology and lower levels of inflammatory cytokines in the infected lungs. Further analysis of immunogenicity showed that the superior protection afforded by the B/D regimen was associated with significantly increased frequency of splenic interleukin‐2 ( IL ‐2) ‐producing CD 4 T cells and increased IL ‐2 production when measured as integrated mean fluorescence intensity post‐vaccination as well. These data suggest that measurement of elevated frequency of IL ‐2‐producing CD 4 T cells or IL ‐2 production in the spleens of vaccinated mice can predict vaccine efficacy, at least in the B/D strategy, and add to the accumulating body of evidence suggesting that BCG prime‐boost strategies may be a useful approach to the control of M . tuberclosis infection.